Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Citizen Petitions On Generic Carve-Outs May Be Whittled Away By FDAAA

Executive Summary

FDA and the generics industry are cautiously optimistic that reforms included in the FDA Amendments Act of 2007 will reduce the approval delays that generics have experienced due to citizen petitions
Advertisement

Related Content

Sandoz Loses Citizen Petition On Carve Outs - Good News For Generics
Sandoz Loses Citizen Petition On Carve Outs - Good News For Generics
Can A REMS Block A Generic? Thalomid Could Be Early Test
Generic 180-Day Exclusivity Forfeiture: What If “Failure” Is Not Your Fault?
Generic 180-Day Exclusivity Forfeiture: What If “Failure” Is Not Your Fault?
Generic 180-Day Exclusivity Forfeiture: What If “Failure” Is Not Your Fault?
Generic Labeling “Carve-Outs” For Marinol Challenged On Safety Grounds
FDARA Citizen Petition Provisions No “Silver Bullet,” Bradshaw Tells GPhA
FDARA Citizen Petition Provisions No “Silver Bullet,” Bradshaw Tells GPhA
Advertisement
UsernamePublicRestriction

Register

PS049909

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel